Correspondence and communication| Volume 65, ISSUE 4, P529, April 2012

Download started.


Reply to discussion: Macrolane is no longer allowed in aesthetic breast augmentation in France. Will this decision extend to the rest of the world?

Published:January 19, 2012DOI:
      I would like to thank Dr. Per Heden, who has extensive experience of Macrolane, for this additional information. Since March 11, 2005, the precautionary principle is part of the French Republic constitution. The scandal PIP (Poly Implant Prothèse) is not the first crisis that led parliamentarians to that decision. The contaminated blood affair, mad cow diseases… have contributed to promote this basic principle a few years ago. This communication is not only the viewpoint of Chaput et al. but also of the AFSSAPS’ expert group who have considered that at the present time, the available scientific literature on hyaluronic acid injections close to the breast parenchyma was insufficient.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Plastic, Reconstructive & Aesthetic Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hedén P.
        • Olenius M.
        • Tengvar M.
        Macrolane for breast enhancement: 12-month follow-up.
        Plast Reconstr Surg. 2011; 127: 850-860
      1. Compte-rendu de la Commission nationale de sécurité sanitaire des dispositifs médicaux. AFSSAPS. Séance du 3 février 2010. Point 5;pp. 8–10.

      Linked Article